FDA Advisers Back Broader Humira Approval
A U.S. Food and Drug Administration advisory panel on Tuesday backed the use of Abbott Laboratories Inc.'s blockbuster anti-inflammatory drug Humira to treat the bowel disease ulcerative colitis, saying its benefits...To view the full article, register now.
Already a subscriber? Click here to view full article